• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $A

    Agilent Technologies Inc.

    Subscribe to $A
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.

    IPO Year: 1999

    Exchange: NYSE

    Website: agilent.com

    Peers

    $BRKR
    $MTD
    $PKI
    $TMO
    $WAT

    Recent Analyst Ratings for Agilent Technologies Inc.

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    11/17/2023$163.00 → $125.00Buy → Neutral
    UBS
    9/28/2023$123.00Mkt Perform
    Bernstein
    See more ratings

    Agilent Technologies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mcdonnell Padraig sold $226,900 worth of shares (2,000 units at $113.45), decreasing direct ownership by 5% to 35,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    8/4/25 4:15:32 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    V.P., Corporate Controller Gonsalves Rodney was granted 9,031 shares, increasing direct ownership by 41% to 30,972 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/18/25 2:43:11 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Dimarco Bret covered exercise/tax liability with 141 shares, decreasing direct ownership by 3% to 5,475 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/7/25 4:04:41 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig sold $177,100 worth of shares (1,508 units at $117.44), decreasing direct ownership by 4% to 37,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/3/25 4:46:35 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.37% to 8,159 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/1/25 1:40:18 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Brown Judy L sold $904 worth of shares (8 units at $116.53), decreasing direct ownership by 0.46% to 1,677 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/23/25 12:12:14 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Brown Judy L was granted 1,677 shares, increasing direct ownership by 21,611% to 1,685 units (SEC Form 4)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/23/25 12:11:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: New insider Brown Judy L claimed ownership of 8 shares (SEC Form 3)

    3/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/23/25 12:09:33 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Soriot Pascal covered exercise/tax liability with 504 shares, decreasing direct ownership by 30% to 1,173 units (SEC Form 4)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/11/25 5:41:20 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 1% to 38,956 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/25 7:36:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shane Snyder to Lead New Agilent Center of Excellence at Georgia Tech Focused on Water and the Environment

    Center of Excellence will feature bio-environmental research to facilitate advancements in environmental health and safety Agilent Technologies Inc. and Georgia Tech today announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering to advance research in environmental sustainability, water recycling, and biologics. Internationally recognized environmental scientist Professor Shane Snyder from the School of Civil and Environmental Engineering at Georgia Tech will lead the Agilent CoE. The CoE will foster collaboration and innovation among researchers, serve as a hub for innovation in environmental characterization, and integrate Agilent's

    8/13/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Expands the Dako Omnis Family with Three New Models to Meet Evolving Pathology Lab Needs

    Agilent Technologies Inc. (NYSE:A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic requirements. With the launch of the Agilent Dako Omnis family, Agilent transitions beyond a one-size-fits-all model to offer a tailored portfolio—empowering labs to select the configuration that best meets their needs. Scalable Solutions for Every Lab—From Routine to Revolutionary. Dako Omnis 110: Built fo

    8/4/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27

    Following an announcement earlier this week, Agilent Technologies Inc. (NYSE:A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innova

    7/17/25 4:30:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces CFO Transition

    Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career. Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named. "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said Pr

    7/15/25 8:30:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Showcase New Products and Innovations at HPLC 2025

    Agilent Technologies Inc. (NYSE:A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical outcomes. The Agilent InfinityLab Pro iQ Series, launched at ASMS 2025, represents the next generation of LC-mass detection. With innovative hardware advancements, the series delivers enhanced sensitivity and analytical performance for oligonucleotides, therapeutic

    6/12/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Smackover Lithium's South West Arkansas Project Receives Royalty Rate Approval From the Arkansas Oil and Gas Commission

    LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of

    5/29/25 8:30:27 AM ET
    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals

    Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

    Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

    5/28/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Names August Specht as Chief Technology Officer

    Agilent Technologies Inc. (NYSE:A) today announced August Specht, Ph.D., has been named the company's Chief Technology Officer. Specht, previously vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific, will join Agilent on June 9. "We are thrilled to welcome August Specht to the Agilent team as we further accelerate the pace of innovation in an ever-changing world through our Ignite Transformation," said Padraig McDonnell, Agilent president and CEO. "August brings more than 25 years of experience designing, developing, and marketing analytical instruments, software, and consumables that support scientific advancement around the worl

    5/28/25 8:30:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces the Enhanced 8850 Gas Chromatograph: Compact, Powerful, and Now Mass Spec-Connected for Superior Analytical Performance

    Agilent Technologies Inc. (NYSE:A) today announced the latest enhancements to the Agilent 8850 Gas Chromatograph (GC), including compatibility with single and triple quadrupole mass spectrometry (MS) systems and related tools and technologies to improve laboratory productivity. The unique design and compact size of the 8850 GC make it one of the fastest and smallest benchtop GC/MS available. It is explicitly designed for labs that require high speed and high performance in a space-saving format. MS compatibility with the 8850 GC significantly boosts its ability to identify and quantify complex samples, making it ideal for applications in chemicals, energy, food, environmental, and forensi

    5/27/25 8:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

    Setting new standards for intelligent mass detection, sensitivity, and sustainability Agilent Technologies Inc. (NYSE:A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse analytical needs of modern laboratories. These advanced, intelligent systems are particularly well-suited for analyzing essential molecules such as therapeutic small molecules, oligonucleotides, peptides, and proteins. The Pro iQ Series is designed to serve a broad range

    5/27/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. SEC Filings

    View All

    Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/8/25 4:15:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Agilent Technologies Inc.

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    7/15/25 8:43:34 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Agilent Technologies Inc.

    144 - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    7/1/25 12:45:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    5/30/25 7:02:43 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    5/28/25 4:06:14 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SD filed by Agilent Technologies Inc.

    SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    5/27/25 4:05:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    5/21/25 9:00:10 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Agilent Technologies Inc.

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    5/2/25 4:01:23 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    4/2/25 4:58:34 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/17/25 4:30:08 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

    2/10/25 6:55:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Agilent with a new price target

    Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

    8/28/24 7:20:29 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Citigroup with a new price target

    Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

    7/10/24 7:22:08 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent downgraded by Wolfe Research

    Wolfe Research downgraded Agilent from Outperform to Peer Perform

    6/27/24 7:18:55 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Agilent with a new price target

    Jefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00

    6/3/24 8:39:10 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Stifel with a new price target

    Stifel upgraded Agilent from Hold to Buy and set a new price target of $163.00 from $145.00 previously

    4/5/24 7:20:49 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wolfe Research initiated coverage on Agilent with a new price target

    Wolfe Research initiated coverage of Agilent with a rating of Outperform and set a new price target of $140.00

    12/13/23 6:47:28 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent downgraded by BofA Securities with a new price target

    BofA Securities downgraded Agilent from Buy to Neutral and set a new price target of $133.00 from $130.00 previously

    12/12/23 6:43:53 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent downgraded by UBS with a new price target

    UBS downgraded Agilent from Buy to Neutral and set a new price target of $125.00 from $163.00 previously

    11/17/23 7:16:33 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bernstein initiated coverage on Agilent with a new price target

    Bernstein initiated coverage of Agilent with a rating of Mkt Perform and set a new price target of $123.00

    9/28/23 7:30:40 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    4/10/24 2:03:52 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    2/13/24 4:58:48 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    2/14/23 12:38:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    2/9/23 10:54:50 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    2/14/22 2:34:30 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    2/9/22 3:16:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    2/16/21 12:23:48 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. Financials

    Live finance-specific insights

    View All

    Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27

    Following an announcement earlier this week, Agilent Technologies Inc. (NYSE:A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innova

    7/17/25 4:30:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces CFO Transition

    Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career. Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named. "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said Pr

    7/15/25 8:30:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

    Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

    5/28/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans

    5/21/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

    Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag

    4/16/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports First-Quarter Fiscal Year 2025 Financial Results

    Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).

    2/26/25 4:04:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted a

    2/19/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results on Feb. 26

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    1/24/25 5:59:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results

    Delivers solid results in Q4; initiates FY25 guidance Fourth-quarter fiscal year 2024 Revenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023. GAAP net income of $351 million; earnings per share (EPS) of $1.22, down 25% from the fourth quarter of 2023. Non-GAAP(2) net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023. Full fiscal year 2024 Revenue of $6.51 billion, down 4.7% on a reported basis and down 4.7% core(1) year-over-year. GAAP net income of $1.289 billion; EPS of $4.43, up 6% year-over-year. Non-GAAP(2) net income of $1.539 billion; EPS of $5.29, down 3% year-over-year. Fiscal year 2025 an

    11/25/24 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Increases Cash Dividend to 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includ

    11/20/24 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. Leadership Updates

    Live Leadership Updates

    View All

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

    New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals while reducing energy consumption up to 30%. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9270251-agilent-unveils-8

    5/23/24 8:04:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

    New instrument delivers the full power and capability of Agilent GCs in a compact design Agilent Technologies Inc., (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals, while reducing energy consumption by up to 30%. Modern labs face the seemingly contrasting goals of maximizing analytical capacity with limited bench space while reducing the overall environmental impact of their opera

    5/23/24 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Padraig McDonnell Assumes Agilent CEO Role

    Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company's CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent's history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501393789/en/Padraig McDonnell (Photo: Business Wire) "It's an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life," McDonnell said. "I'm proud of how we forge partnerships with our

    5/1/24 8:45:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fundbox Appoints Hilliard Terry to Board of Directors

    SAN FRANCISCO, CA, June 22, 2021 (GLOBE NEWSWIRE) -- Fundbox, the financial platform for small businesses, announced today that it has appointed Hilliard Terry to its Board of Directors. Mr. Terry is an experienced executive leader, corporate board member and advisor to private equity backed portfolio companies.   Mr. Terry currently serves on the board of directors of Umpqua Holdings Corporation (NASDAQ:UMPQ), a financial services company. He also serves on the board of directors of Upstart Holdings, Inc. (NASDAQ:UPST), a leading artificial intelligence consumer lending platform, and on the board of TLG Acquisition One Corporation (NYSE:TLGA), a special purpose acquisition company. "H

    6/22/21 12:00:00 PM ET
    $UPST
    $TGH
    $A
    Finance: Consumer Services
    Finance
    Diversified Commercial Services
    Consumer Discretionary

    Agilent Names Allison Ballmer Senior Vice President of Strategy and Corporate Development

    SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.(NYSE: A) is pleased to announce Allison Ballmer has been named the company’s new senior vice president of Strategy and Corporate Development, reporting to Agilent President and CEO Mike McMullen. Ballmer will lead the corporate development team in identifying, developing, and evaluating merger-and-acquisition plans globally, as well as program management of integrations. She also will lead enterprise strategy while collaborating with Agilent businesses groups to drive critical growth initiatives across the company. Ballmer will serve as a key member of the executive staff and as an adviser to the CEO to help shape th

    1/15/21 1:37:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aon Declares Quarterly Dividend

    DUBLIN, Jan. 11, 2021 /PRNewswire/ -- Aon plc (NYSE: AON), the leading global professional services firm providing a broad range of risk, retirement and health solutions, announced today that the Board of Directors has declared a quarterly cash dividend of $0.46 per share on outstanding Class A Ordinary Shares. The dividend is payable February 12, 2021 to shareholders of record on February 1, 2021. About Aon Aon plc (NYSE: AON) Aon is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatilit

    1/11/21 4:30:00 PM ET
    $AON
    $A
    Specialty Insurers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials